

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(21) International Application Number: PCT/CA97/00172 (22) International Filing Date: 12 March 1997 (12.03.97) (30) Priority Data: 60/013,401 14 March 1996 (14.03.96) US 2,173,2724 2 April 1996 (02.04.96) CA (71) Applicant (for all designated States except US): HYAL PHAR-MACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA). Publisher	ated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TM), European patent (AT, BE, CH, DE, DK, ES, FI, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent
(22) International Filing Date: 12 March 1997 (12.03.97) (30) Priority Data: 60/013,401 14 March 1996 (14.03.96) US 2,173,272\(\times\) 2 April 1996 (02.04.96) CA (71) Applicant (for all designated States except US): HYAL PHAR-MACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): PILARSKI, Linda, May [US/CA]; Box 63, Site 3, R.R. #4, Stony Plain, Alberta	, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TM), European patent (AT, BE, CH, DE, DK, ES, FI, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent
(74) Agent: HUGHES, Etigson; Suite 200, 175 Commerce Valley Drive West, Thomhill, Ontario L3T 7P6 (CA).	, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD,). th international search report.

(57) Abstract

The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.